February 28, 2012 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys' fees and expenses and dismissed the action with prejudice.
February 23, 2012 - The court held a final settlement meeting.

November 3, 2011 - The court preliminarily approved the settlement.

September 21, 2011 - Parties filed a stipulation of settlement.

August 9, 2010 - The court denied the defendants' motion to dismiss.

February 19, 2010 - Defendants filed a motion to dismiss.

January 20, 2010 - The lead plaintiff filed a corrected amended consolidated complaint.

January 18, 2010 - The lead plaintiff filed an amended consolidated complaint.

December 2, 2009 - The court granted the defendants' motion to dismiss and granted plaintiff leave to file a second amended complaint.

July 17, 2009 - Defendants filed a motion to dismiss.

May 18, 2009 - The lead plaintiff filed an amended consolidated complaint on behalf of investors who purchased MRX common shares between October 30, 2003 and September 23, 2008. The lead plaintiff alleges that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between October 30, 2003 and September 23, 2008.

March 10, 2009 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

December 2, 2008 - Lead plaintiff motions were filed.

October 3, 2008 - An investor in shares of Medicis Pharmaceutical Corporation (NYSE: MRX now trading on the NYSE sheets as VRX due to Valeant Pharmaceuticals International Inc's acquisition of Medicis Pharmaceutical Corporation) filed a lawsuit in the U.S. District Court for the District of Arizona against Medicis Pharmaceutical Corporation over alleged violations of Federal Securities Laws.

According to the complaint the plaintiff charges Medicis Pharmaceutical Corporation and certain of its officers and directors with violations of the Securities Exchange Act of 1934. The complaint alleges that between October 30, 2003 through September 24, 200 defendant issued materially false and misleading statements regarding Medicis Pharmaceutical Corporation’s business and financial results.

The complaint charges that Medicis Pharmaceutical Corporation and certain of its officers violated Sections 10(b) and 20(a) of the Exchange Act by issuing materially inaccurate financial statements to the investing public. On September 24, 2008, Medicis Pharmaceutical Corporation announced that it intends to restate its financial statements for each of the accounting periods beginning July 1, 2003 and ending June 30, 2008, and that investors can no longer rely on these financial statements. The restatement is necessary because Medicis Pharmaceutical Corporation Pharmaceutical Corporation applied an improper accounting method in determining reserves for sales returns during the Class Period. News of the pending restatement caused Medicis Pharmaceutical Corporation’s stock price to fall significantly, damaging investors.